"Aethlon Medical enrols first patient in trial of Hemopurifier device for cancer " was originally created and published by ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

Keytruda (pembrolizumab ... or appropriate for all patients or all specific uses.

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...

Combination Dose Escalation Tumor Response: Encouraging preliminary signs of anti-tumor activity were observed with MDNA11 in combination with KEYTRUDA in dose escalation cohorts 1 and 2. Among 5 ...

Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

KEYTRUDA, in patients with advanced solid tumors. KVA12123 cleared all six monotherapy dose levels and the second of four cohorts in combination with pembrolizumab. KVA12123 was well tolerated with no ...

On Monday, Merck & Co Inc (NYSE:MRK) and Moderna, Inc. (NASDAQ:MRNA) announced the initiation of INTerpath-009, a pivotal ...

Patient Enrolled at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon's Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier® ...

The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...